Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss

NCT05300048 is registered in ClinicalTrials.gov with Faeth Therapeutics as lead sponsor.

NCT NCT05300048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05300048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss
Lead sponsor
Faeth Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
April 22, 2022
Completion date
April 30, 2025
Enrollment
34 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, pik3ca mutation, pten loss of function mutation